Completed
PHASE3
INTERVENTIONAL
NCT05996848
A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This study will look at how well the new medicine CagriSema helps people with excess body weight losing weight compared to a "dummy" medicine and a medicine called semaglutide. Participants will either get CagriSema, a dummy medicine or semaglutide. Which treatment participants get is decided by chance. Participants will take one injection once a week. The study medicine will be injected briefly with a thin needle, typically in the stomach, thighs or upper arms. The study will last for about 1 year.
Interventions
Name:
Cagrilintide
Type:
DRUG
Description:
Participants will receive 2.4 mg cagrilintide subcutaneously.
Name:
Semaglutide
Type:
DRUG
Description:
Participants will receive 2.4 mg semaglutide subcutaneously.
Name:
Placebo Semaglutide
Type:
DRUG
Description:
Participants will receive placebo matched to semaglutide subcutaneously.
Name:
Placebo Cagrilintide
Type:
DRUG
Description:
Participants will receive placebo matched to cagrilintide subcutaneously.
Primary Outcomes
Measure:
CagriSema 2.4 mg/2.4 mg versus placebo: Relative change in body weight
TimeFrame:
From baseline (week 0) to end of treatment (week 44)
Description:
Measured in percentage (%)
Measure:
CagriSema 2.4 mg/2.4 mg versus placebo: Number of participants who achieve (yes/no): Body weight reduction greater than or equal to 5%
TimeFrame:
From baseline (week 0) to end of treatment (week 44)
Description:
Measured as count of participants
Trial Information
NCT ID
NCT05996848
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
Novo Nordisk A/S
Last Updated
December 15, 2025